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CASE REPORT
Rhabdomyomas are the most common fetal car-
diac tumors with an estimated incidence of 1 in
16,000 live births.1 Cardiac rhabdomyomas are
hamartomas that are usually multiple and may
involve the myocardium, endocardium, pericar-
dium, papillary muscles, cardiac valves, and the
pulmonary and aortic outflow tracts.1 Cardiac
rhabdomyomas are prenatal echocardiographic
markers for tuberous sclerosis complex (TSC).
Prenatally diagnosed cardiac rhabdomyomas
are associated with TSC in 50–79% of cases.2
Tworetzky et al3 ffound that 95% (61 of 64 cases) o
fetuses and neonates with multiple cardiac tumors
had TSC. Most cardiac rhabdomyomas have favor-
able outcome with regression beyond the third
f trimester and complete resolution of 80% o
ttumors during infancy and childhood withou
major complications.4,5 However, rhabdomyomas
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TSC is caused by mutations in the genes TSC1 and TSC2. We report a 28-year-old, gravida 5, para 2,
woman with an uncomplicated pregnancy until prenatal ultrasound at 34 weeks’ gestation revealed fetal
cardiac tumors. Ultrafast magnetic resonance imaging (MRI) at 36 weeks’ gestation showed cardiac rhab-
domyomas and small subependymal tubers. At 39 weeks’ gestation, a 2262 g female infant was delivered
uneventfully. Postnatal echocardiography confirmed cardiac rhabdomyomas and MRI verified small
cerebral subependymal tubers. Mutational analysis of TSC1 and TSC2 genes using denaturing high-
tperformance liquid chromatography and direct sequencing of the genes was performed and revealed tha
the parents had wildtype DNA, while the proband was heterozygous for a novel de novo nonsense muta-
tion, c.4830 G > A, in exon 36 of the TSC2 gene, resulting in a change of codon 1610 TGG (tryptophan) to
TGA (stop codon). The mutation predicted a W1610X premature termination of the tuberin protein. These
findings support an association between a TSC2 de novo nonsense mutation and prenatally detected car-
diac rhabdomyomas and cerebral tuberous sclerosis. Familial molecular analysis of TSC1 and TSC2 in
cases with prenatally diagnosed cardiac rhabdomyomas and cerebral tuberous sclerosis lesions is helpful
in prenatal diagnosis and genetic counseling. [J Formos Med Assoc 2006;105(7):599–603]
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in association with brain tumors represent a
poorer prognosis, such as mental retardation and
severe epilepsy.6 Perinatal detection of associated
cerebral lesions informs the parents about the
existence of the condition and provides clinicians
with further information required to confirm the
diagnosis. Here, we report a case of prenatally 
diagnosed cardiac rhabdomyomas and cerebral
tuberous sclerosis associated with a mutation 
in the TSC gene detected by denaturing high-
performance liquid chromatography (DHPLC).
Case Report
A 28-year-old, gravida 5, para 2, woman had an
uncomplicated pregnancy until 34 weeks’ ges-
tation when intrauterine growth restriction and
fetal cardiac tumors were detected by routine
ultrasound. The woman and her husband were
healthy and did not have any family history of
TSC or cardiac tumors. Level II ultrasonography
at 36 weeks’ gestation revealed fetal cardiac rhab-
domyomas arising from the interventricular sep-
tum and the left ventricle with no evidence of
brain abnormality. Ultrafast magnetic resonance
imaging (MRI), however, revealed multiple small
subependymal tubers. Subsequent weekly follow-
ups showed no signs of cardiac compromise. At
39 weeks’ gestation, a 2262 g female infant was
delivered uneventfully. Postnatal echocardiogra-
phy confirmed cardiac rhabdomyomas and MRI
scans verified small cerebral subependymal tubers.
DNA preparation
DNA samples were extracted from peripheral
whole blood of the proband and relevant family
members by using a Puregene DNA isolation kit
(Gentra Systems, Inc., Minneapolis, MN, USA)
according to the manufacturer’s instructions.
Polymerase chain reaction (PCR)
The PCR primers used for mutational analysis of
the TSC1 and TSC2 genes in TSC patients were
as previously described.6 To detect the mutations
in the TSC1 and TSC2 genes, the primer pairs
were designed to amplify all exons in the TSC1
and TSC2 genes spanning all coding regions and
the intron–exon boundaries. To detect the muta-
tions in the TSC r2 gene, the intronic primer pai
5’-AGGCAGTAGCCGAGATCAGC-3’ (sense) and
5’-GCAGGGGTGAGCTCACTATC-3’ (antisense)
spanning the coding region and the intron–exon
boundaries of exon 36 of the TSC2 gene were
used. This primer-pair combination generated a
fragment of 421 bp.
PCR techniques for the DNA fragments were
gperformed in a total volume of 25 μL containin
100 ng of genomic DNA, 0.12 μM of each primer,
100 μM dNTPs, 0.5 units of AmpliTaq GoldTM
enzyme (PE Applied Biosystems, Foster City,
CA, USA), and 2.5 μL of GeneAmp 10× buffer II
(10 mM Tris-HCl, pH = 8.3, 50 mM KCl), in 2 mM
MgCl2 as provided by the manufacturer. Amplifi-
cation was performed in a multiblock system
thermocycler (ThermoHybaid, Ashford, UK).
DHPLC analysis
tThe Transgenomic Wave Nucleic Acid Fragmen
Analysis System (Transgenomic Inc., San Jose,
CA, USA) was used for analyzing heterodu-
plexes. DHPLC was carried out using automated
HPLC instrumentation equipped with a DNASep
 column (Transgenomic Inc.). DHPLC-grade
acetonitrile (9017-03, JT Baker, Phillipsburg, NJ,
USA) and triethylammonium acetate (TEAA,
Transgenomic Inc.) were used to constitute the
mobile phase. The mobile phases comprised
0.05% acetonitrile in 0.1 M TEAA (eluent A) and
25% acetonitrile in 0.1 M TEAA (eluent B).
For heteroduplex detection, crude PCR prod-
ucts were subjected to an additional 3-minute
95°C denaturing step followed by gradual rean-
nealing from 95°C to 65°C over a period of 30
wminutes prior to analysis and eluted at a flo
rate of 0.9 mL/minute. Amplification products
were then separated over a 4.5-minute period
at the temperatures required for successful reso-
lution of heteroduplex molecules of 63.5°C and
64.5° rC through a linear gradient (58–67% fo
63.5°C and 57–68% for 64.5° cC). The specifi
 values for all analyses were adjusted using an
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algorithm provided by the system control soft-
ware (WAVEmaker, version 4.1.42; Transgenomic
Inc.).
A volume of 8 μL was injected for analysis of
each PCR run. Heterozygous profiles were identi-
fied by visual inspection of the chromatograms
on the basis of the appearance of additional ear-
lier elution peaks. The analysis of an individual
sample took about 8 minutes, including regener-
ation and equilibration of the column after each
analysis. Heterozygous control probes were used
to confirm system performance and the accuracy
of the specified oven temperature. In this famil-
ial analysis, all of the exons in TSC1 and TSC2
genes span all the coding regions and the intron–
exon boundaries after PCR amplification were
analyzed by DHPLC.
Direct sequencing
PCR products were purified by solid-phase extrac-
tion, and bidirectionally sequenced using the
Applied Biosystems Taq DyeDeoxy terminator
cycle sequencing kit (Applied Biosystems) accord-
ing to the manufacturer’s instructions. Sequen-
cing reactions were separated on an Applied
Biosystems 3100 sequencer.
Results
Mutation analysis by DHPLC and direct sequenc-
ing of the coding region and exon–intron bound-
aries of exon 36 of the TSC2 gene showed that the
parents had wildtype DNA, while the proband
was heterozygous for a novel de novo nonsense
mutation, c.4830 G > A, in exon 36 of the TSC2
gene. This mutation resulted in a change of codon
1610 TGG (tryptophan) to TGA (stop codon), and
predicted a W1610X premature termination of
the tuberin protein (Figure).
Discussion
The infant with prenatally diagnosed cardiac
rhabdomyomas and cerebral tuberous sclerosis
had a novel nonsense mutation of c.4830 G > A in
exon 36 of the TSC2 gene detected by DHPLC.
Molecular investigation of the parents by DHPLC
did not show this mutation. Rapid mutational
investigation of TSC ggenes in parents followin
the delivery of babies with TSC and known muta-
tions in the TSC genes by DHPLC is very helpful
for genetic counseling and prenatal diagnosis in
subsequent pregnancies. TSC is an autosomal-
dominant disorder. The parents of affected babies
tmay have the same TSC disorder but exhibi  
reduced penetrance without significant external
cmanifestations or have only low-level somati
mosaicism. Preimplantation genetic diagnosis
provides an acceptable alternative for parents
yaffected with TSC, and may be performed b
chorionic villus sampling or amniocentesis.
TSC is caused by mutations in the tumor-
suppressor genes, TSC1 and TSC2. The TSC1 gene
(OMIM *605284), mapped to chromosome 9q34,
has 21 coding exons and  two leader exons and
encodes a 130 kDa (1164 amino acids) protein
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TSC
[wt] [wt]
TSC2 gene exon 36, c.4830 G > A (1610 Trp > X)
iF gure. ff boundaries oDHPLC and sequence analysis o  the exon intron –
exon 36 of the TSC e father and2 gene in the proband and parents. Th
erozygous for mother have wildtype DNA [wt], while the proband is het
a de novo nonsense mutation, c.4830 G > the A, in exon 36 of TSC2 gene,
TGA (stop resulting in a change of codon 1610 TGG (tryptophan) to codon).
the tuberinThe mutation predicts a W1610X premature termination of 
protein.
named hamartin.7 The TSC2 gene (OMIM
*191092), mapped to chromosome 16p13.3, has
41 coding exons and one leader exon and encodes
a 198 kDa (1807 amino acids) protein named
tuberin.8,9 Since two-thirds TSC cases are sporad-
ically caused by new mutations10 and the sizes of
the TSC genes are quite large, effective methods
for analyzing mutations in both TSC1 and TSC2
are required. DHPLC is a recently developed
high-capacity technique for the analysis of the
entire human genome, allowing automated de-
tection of single-base substitutions and small
insertions and/or deletions, that has been appl-
ied for rapid mutation screening of TSC1 and
TSC2.11–17 In this case, we detected a novel de novo
nonsense mutation in the TSC2 gene associated
with prenatally diagnosed cardiac rhabdomy-
omas and cerebral tuberous sclerosis using
DHPLC. This technique has advantages over
other gel-based methods, such as single-stranded
conformation analysis, heteroduplex analysis,
and denaturing gradient gel electrophoresis in
terms of time, money, and effort.11,12,14,15 Further,
DHPLC can detect TSC1 and TSC2 mutations in
TSC patients with low-level somatic mosaicism,
even when manual or automated direct sequenc-
ing is unable to identify the mutant alleles.14,17
The most significant finding of this sporadic
TSC2 mutation is its support of an association
between de novo TSC2 mutation and in utero phe-
notype of cardiac rhabdomyomas and cerebral
TSC. Mutational analysis of TSC1 and TSC2 and
phenotypic associations revealed increased severity
of TSC2 in the disease in multiple organs as com-
pared with TSC1.6,18 Sancak et al observed that 
de novo TSC2 mutations were associated with a
more severe phenotype than de novo TSC1 muta-
tions, and that patients with de novo TSC2 muta-
tions had a more severe phenotypic spectrum
than patients with familial TSC2 mutations.19
This report supports these findings and shows the
effect of a TSC2 de novo nonsense mutation on
the intrauterine development of cardiac rhabdo-
myomas and cerebral TSC.
In summary, we describe a correlation of a
TSC2 de novo nonsense mutation with prenatally
detected cardiac rhabdomyomas and cerebral
ftuberous sclerosis. Familial molecular analysis o
TSC1 and TSC2 should be performed in all cases
with prenatally diagnosed cardiac rhabdomyomas
and cerebral tuberous sclerosis lesions to facilitate
genetic counseling and prenatal diagnosis in sub-
sequent pregnancies. The identification of a TSC1
or TSC2 mutation is important for confirmation
cof the diagnosis, clinical evaluation, therapeuti
management, and preventive measures.
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